PLEASANTON, Calif., Nov. 7, 2016 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of KAPA® RNA HyperPrep product, a robust RNA library preparation solution for a range of sample types and input amounts. These kits provide a single-tube workflow and decrease processing time by 30 percent1 while maintaining quality.
The KAPA RNA HyperPrep kits utilize a novel chemistry that enables the combination of enzymatic steps and fewer reaction purifications, resulting in a truly streamlined solution for the preparation of high-quality RNA-seq libraries. These strand-specific workflows can be completed in a standard workday while generating high-quality libraries from challenging samples such as formalin-fixed, paraffin-embedded (FFPE).
"We are pleased to bring our successful DNA HyperPrep technology to the RNA application space providing researchers high performance in a single-tube workflow," said Neil Gunn, Global Head of Roche Sequencing Solutions. "With the advancement of sequencing platforms and the wide range of applications being explored by researchers, it is essential to use robust and streamlined methods for sample preparation."
In addition to a number of next generation sequencing (NGS)-related acquisitions and partnerships announced in the last two years, Roche continues to invest in the development of innovative library preparation products, an important part of an end-to-end sequencing solution. The development of the RNA HyperPrep product line is a result of this investment.
For more information about RNA HyperPrep go to: www.kapabiosystems.com/mRNAHyper
1Data on file.
For Research Use Only. Not for use in diagnostic procedures.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives.
Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices.
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
For further information, please contact:
Roche Sequencing Solutions
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/roche-launches-new-rna-hyperprep-product-line-300358050.html